Heartcore Capital

Heartcore Capital (formerly Sunstone Capital) is an early-stage venture capital firm with separate funds and investment teams dedicated to technology and life science venture investing. The Firm invests in opportunities across the life science sector, including therapeutics, medical technology and diagnostics. Within the technology sector, Sunstone focuses on communication technologies, components, software and digital media. It typically makes its initial investment in companies raising Series A/B rounds, but also may invest at an earlier stage.

TypeInvestor
HQKøbenhavn, DK
Founded2007
Websitesunstone.eu
Cybersecurity ratingAMore
Heartcore Capital was founded in 2007 and is headquartered in København, DK

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Heartcore Capital

Peter Benson

Peter Benson

Chairman & General Partner
Søren Lemonius

Søren Lemonius

Managing General Partner
Sten Verland

Sten Verland

General Partner
Claus Andersson

Claus Andersson

General Partner
Robert Cobuzzi

Robert Cobuzzi

Venture Partner
Merete Lundbye Møller

Merete Lundbye Møller

Venture Partner, General Counsel
Show more

Heartcore Capital Office Locations

Heartcore Capital has an office in København
København, DK (HQ)
Store Strandstræde 18
Show all (1)

Heartcore Capital Online and Social Media Presence

Embed Graph

Heartcore Capital Blogs

Ascelia Pharma gets US patent for 2nd generation Mangoral

Indlægget Ascelia Pharma gets US patent for 2nd generation Mangoral blev først udgivet på Sunstone.

MinervaX raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

Indlægget MinervaX raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials blev først udgivet på Sunstone.

The FDA grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma

Indlægget The FDA grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma blev først udgivet på Sunstone.

Increasing the investor return multiple with an IPO?

Indlægget Increasing the investor return multiple with an IPO? blev først udgivet på Sunstone.

Are big financing rounds and venture star multiples a realistic expected outcome?

Indlægget Are big financing rounds and venture star multiples a realistic expected outcome? blev først udgivet på Sunstone.

Sunstone portfolio company Galecto in successful IPO on Nasdaq Global Market in the US.

Indlægget Sunstone portfolio company Galecto in successful IPO on Nasdaq Global Market in the US. blev først udgivet på Sunstone.
Show more

Heartcore Capital Frequently Asked Questions

  • When was Heartcore Capital founded?

    Heartcore Capital was founded in 2007.

  • Who are Heartcore Capital key executives?

    Heartcore Capital's key executives are Peter Benson, Søren Lemonius and Sten Verland.

  • What is Heartcore Capital revenue?

    Latest Heartcore Capital annual revenue is kr3.8 m.

  • Where is Heartcore Capital headquarters?

    Heartcore Capital headquarters is located at Store Strandstræde 18, København.

  • Where are Heartcore Capital offices?

    Heartcore Capital has an office in København.

  • How many offices does Heartcore Capital have?

    Heartcore Capital has 1 office.